Author: Jennifer Levy

Travel Grant Program for Early Career Investigators

Coalition to Cure Calpain 3 will award Travel Grants to foster early career investigators who are currently conducting research in the areas of limb-girdle muscular dystrophy type 2A (LGMD2A/R1) or Calpain 3. The grants support travel expenses to attend relevant

Our GIVING TUESDAY fundraiser starts NOW!

Champion Coalition to Cure Calpain 3’s cause to raise $50,000 for LGMD2A/R1 gene therapy research. Every dollar donated between now and December 1, 2022 will be matched, up to $25,000 by a family motivated to drive a gene therapy cure.

New LGMD2A/R1 Mice: Novel tools for drug development

Coalition to Cure Calpain 3 (C3) is excited to announce the generation of four mouse models of limb-girdle muscular dystrophy type 2A (LGMD2A/R1). These mouse models were developed and characterized as part of a research grant from C3 to Dr.

Your voice made a difference!

THANK YOU to all those families impacted by limb-girdle muscular dystrophy types 2A, 2C, 2D, 2E, 2F, and 2I who made their voices heard at the LGMD EL-PFDD! Whether you were on camera, called in, submitted written comments, or participated

The LGMD EL-PFDD is just one week away!

Join us for this important LGMD event on September 23rd beginning at 10:00 AM EDT and make YOUR VOICE HEARD. Bookmark www.lgmdpfdd.com so you can view and participate live.

Together we are STRONGER: 8th Annual LGMD Awareness Day is coming up!

There is great strength in awareness, understanding, and unity. The LGMD community demonstrates global connectivity each year when we campaign together and gain recognition for LGMD. With over 30 different genetic types of LGMD, the act of collaborating globally makes

Casimir Recruiting LGMD2A/R1 Patients for At-Home Study

The Casimir LGVA study is quickly filling! We are specifically seeking individuals with LGMD2A who can walk across a room and stand up from sitting on a couch to participate. Email LGMDS@casimirtrials.com or call (800)542-0948 for more information.

Pre-registration is now open for the LGMD EL-PFDD Meeting with FDA and other stakeholders

PRE-REGISTER NOW FOR THE LGMD EXTERNALLY-LED PATIENT-FOCUSED DRUG DEVELOPMENT MEETING TO BE HELD ON FRIDAY, SEPTEMBER 23. This no-cost, public virtual meeting is open to those living with LGMD2A, their families and caregivers, physicians, clinicians, industry/pharma representatives, academic researchers, FDA

Limb-girdle muscular dystrophy coalition to host externally-led patient focused drug development meeting

C3 is excited to announce that we’ve teamed up with the LGMD2D Foundation, the Kurt+Peter Foundation, CureLGMD2I, the McColl-Lockwood Laboratory for Muscular Dystrophy Research, and the Speak Foundation to host an Externally-Led Patient Focused Drug Development (EL-PFDD) meeting with the

It’s Official: The LGMD community celebrates adoption of ICD-10 diagnostic codes for LGMD

After a two year campaign, those with LGMD will now have a diagnostic code that matches their diagnosis! C3 is proud to have played a role in this victory alongside our friends and advocacy partners, including the Muscular Dystrophy Association,